Wire · operational-macro
FDA grants orphan drug status to Neuren's NNZ-2591 for newborn brain injury
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 3 November 2026 · Fusion42 review
Neuren Pharmaceuticals received orphan drug designation from the FDA for NNZ-2591, targeting neonatal hypoxic-ischemic encephalopathy (HIE), a serious brain injury in newborns. The designation provides marketing exclusivity and fee waivers, with clinical trials planned after required juvenile animal safety studies.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
You can now compete for a rare disease drug market with seven years of exclusivity in the US. Start building regulatory and clinical plans around orphan drug opportunities before the IND application in 2027.
◆ Coverage
1 source · 2 Nov 2026
◆ Related on Wire
◆ Topics